Wyss Zurich Wyss Zurich
Wyss Zurich Wyss Zurich
Wyss Zurich
Wyss Zurich Wyss Zurich
  • About us
    • Wyss Zurich Model
    • Project Application Process
    • Wyss Zurich Factsheets
  • Technology Platforms
    • Regenerative Medicine Technologies Platform
    • Robotics Technologies Platform
  • Projects
    • Wyss Zurich projects
      • CeNeReg
      • hemotune
      • LifeMatrix
      • Liver4Life
      • MUVON
      • Nanoflex
      • OxyPrem
      • Phire
      • Recolony
      • Somagenetix
      • Voliro
    • Outreach projects
      • mint & pepper
      • PATHOS
    • Completed projects
      • ANYmotion
      • denovoSkin
      • ETIMSred
      • HYLOMORPH
      • Rosie
      • Seervision
      • Sevensense
      • SwissProsthetics
      • Wingtra
      • Zurich Eye
  • People
    • Leadership & Executive Team
    • Board
    • Evaluation Board
    • Faculty
    • Project-Teams
    • Platform-Teams
  • Newsroom
  • Jobs
  • Contact
  • prev
  • Search

CeNeReg

Antibodies against Nogo-A to enhance regeneration of the injured central nervous system

Nerve fibers in the adult central nervous system (i.e. spinal cord and brain) fail to regenerate after injury, and to date there are no therapies for enhancing their repair. Spinal cord injuries affect people’s lives in a dramatic and long-term fashion, and the social and economic burden of life-long care is enormous.

For a long time there was a dogma that damaged fiber tracts of the central nervous system could not regenerate. However, there is accumulating evidence that specific inhibitory molecules found in myelin (protective layer around nerve fibers) are responsible for the absence of nerve fiber regeneration and the poor functional recovery after injury. This concept, as well as the discovery of the most potent currently known of such growth inhibitors, the membrane protein Nogo-A, were discovered in Zurich by Professor Martin Schwab and his group. His team also demonstrated that antibodies blocking the function of Nogo-A led to long-distance regeneration of injured nerve fibers in the spinal cord of monkeys and rats, and greatly improved their functional recovery.

Based on these promising preclinical results, a phase I (first-in-man) clinical trial in patients with spinal cord injury was conducted, proving excellent safety and tolerability of a human anti-Nogo-A antibody. With the support of the Regenerative Medicine Technologies Platform of Wyss Zurich, the team will now produce a new batch of this therapeutic anti-Nogo-A antibody. This antibody will enable the critical transition to phase II clinical trials, aimed to determine clinical efficacy of the anti-Nogo-A antibody in patients with spinal cord injury. 

Beyond the field of spinal cord injury, these clinical studies will serve as a model for other disorders where nerve fibers of the central nervous system become injured, and may thus have a broad impact for the treatment of neurological diseases in general. A positive outcome of the planned clinical trials would be a real breakthrough in neurology, neuroscience and the field of tissue regeneration and repair.

 

Download CeNeReg factsheet

 

Watch a related video produced by the Swiss Television (SRF) in 2014: Hoffnung für Gelähmte (in German)
 

FUNDING PARTNERS 
Co-funded by the Horizon 2020 Framework Programme of the European Union 
European Research Council
Swiss National Science Foundation
Christopher & Dana Reeve Foundation

Share this article:
twitter-sharetwitter-sharelinkedin-sharelinkedin-sharefacebook-sharefacebook-shareemail-shareemail-share

Team

CeNeReg

Steiner Steiner

Bettina Steiner

Project Leader

 

Mentor: Martin Schwab


CeNeReg

News

06-04-22 - Event

The Wyss Zurich workshop - for school classes of the secondary level I and II
read full article

01-04-20 - News

Wyss Zurich says thank you
read full article

04-12-19 - Event

Zukunftstag
read full article

14-03-19 - Event

Seminar Translational and Clinical Wyss Zurich Projects
read more

More News


More Wyss Zurich projects

hemotune

Restoring immune balance in sepsis

LifeMatrix

Tissue-engineered human matrices to repair and regenerate the heart

Liver4Life

Regeneration of the human liver outside of the body

MUVON

Regain control through personalized muscle regeneration

Nanoflex

Advancing medical robotic interventions

OxyPrem

Brain oxygen measurement for preterm infants

Phire

Antibody-enabled blood stem cell transplantation

Recolony

Bacteria-based cancer therapy

Somagenetix

Gene therapy solutions for patients with severe inherited diseases

Voliro

Advanced flying robots to revolutionize work at height

Project description
Video
Team
News

Wyss Zurich Translational Center
ETH Zurich / University of Zurich
Weinbergstrasse 35, WEH
8092 Zurich
Switzerland

  • Newsletter
  • Media
  • Legal Disclosure
  • Photo and Video Disclaimer
  • Imprint / Disclaimer
Follow Us:
linkedin-share twitter-share instagram youtube-share
Wyss Zurich Footer Logos Wyss Zurich Footer Logos
Scroll Top Scroll Top
Download